Researcher
Anna Sablina
- Disciplines (Flanders Institute for Biotechnology):Analysis of next-generation sequence data, Cell death, Cancer biology
- Disciplines (KU Leuven):Laboratory medicine, Palliative care and end-of-life care, Regenerative medicine, Other basic sciences, Other health sciences, Nursing, Other paramedical sciences, Other translational sciences, Other medical and health sciences
Affiliations
- Laboratory for Mechanisms of Cell Transformation (VIB-KU Leuven) (Division)
Responsible
From1 Jan 2017 → Today - Laboratory for Mechanisms of Cell Transformation (VIB-KU Leuven) (Division)
Member
From1 Jan 2017 → Today - Sablina Lab
Responsible
From1 Jan 2017 → Today - Department of Human Genetics (Department)
Member
From16 Apr 2009 → 31 Dec 2016
Projects
1 - 10 of 26
See also Anna Sablina for projects of Flanders Institute for Biotechnology.
Here below the projects of KU Leuven.
- Targeting RAS for schwannomatosis treatmentFrom29 Oct 2025 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Targeting RAS degradation via the LZTR1 adaptor: structural foundations for developing novel anti-RAS therapeuticsFrom1 Sep 2025 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Understanding the mechanisms underlying the intrinsic resistance of human cancers to RAS degradersFrom1 Apr 2025 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- combiTAC, a novel targeted protein degradation approach for RAS-driven diseaseFrom1 Jan 2025 → TodayFunding: FWO research project (including WEAVE projects)
- Activating negative regulators of KRAS signaling as a novel anticancer paradigmFrom1 Oct 2024 → TodayFunding: Fund Recuperation Fiscal Exemption, BOF - projects
- KRAS-AlphaTACs: a novel class of biotherapeutics to target KRASFrom18 Sep 2024 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Molecular structure and pharmacological activation of LZTR1 towards novel anticancer therapiesFrom5 Sep 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Mapping the functional role of the low copy repeats in the phenotypic variability of the 22q11.2 Deletion SyndromeFrom27 Jan 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Optimize single -cell sequence approaches in PDACFrom14 Nov 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Micropeptides as novel biomarkers and precision medicine targets in cancerFrom26 Sep 2022 → 26 Jan 2023Funding: Own budget, for example: patrimony, inscription fees, gifts
Publications
1 - 10 of 54
See also Anna Sablina for publications of Flanders Institute for Biotechnology.
Here below the publications of KU Leuven.
- Enrichable cross-linkers for mapping direct protein interactions(2025)Published in: Genome BiologyISSN: 1474-760XIssue: 1Volume: 26
- Inhibition of NR2F2 restores hormone therapy response to endocrine refractory breast cancers(2025)Published in: Science Translational MedicineISSN: 1946-6234Issue: 801Volume: 17
- Genetically encoding ε-N-methacryllysine into proteins in live cells(2025)Published in: Nature CommunicationsISSN: 2041-1723Issue: 1Volume: 16
- Intrinsic temperature increase drives lipid metabolism towards ferroptosis evasion and chemotherapy resistance in pancreatic cancer(2024)Published in: Nature CommunicationsISSN: 2041-1723Issue: 1Volume: 15
- The role of LZTR1 in RAS-driven tumorigenesis(2024)
- Allosteric nanobodies to study the interactions between SOS1 and RAS(2024)Published in: NATURE COMMUNICATIONSISSN: 2041-1723Issue: 1Volume: 15
- K128 ubiquitination constrains RAS activity by expanding its binding interface with GAP proteins(2024)Published in: EMBO JournalISSN: 0261-4189Issue: 14Volume: 43Pages: 2862 - 2877
- Cracking the Ubiquitin Code of the RAS GTPases(2024)
- TIPRL1 and its ATM‑dependent phosphorylation promote radiotherapy resistance in head and neck cancer(2024)Published in: Cellular OncologyISSN: 2211-3428Issue: 3Volume: 47
- Targeted STAT1 therapy for LZTR1-driven peripheral nerve sheath tumor(2023)Published in: Cancer CommunicationsISSN: 2523-3548Issue: 12Volume: 43Pages: 1386 - 1390
Patents
1 - 1 of 1